The new 13-valent pneumococcal conjugate vaccine (Prevnar 13) is picking up right where the 7-valent version left off.
It has been 10 years since the introduction of the 7-valent pneumococcal conjugate vaccine (Prevnar). Overall in the United States, the program has had significant success, with an approximate 65%-70% reduction in invasive disease due to Streptococcus pneumoniae. We’ve also seen substantial reductions in acute otitis media (AOM) and community-acquired pneumonia (CAP).
